Antibiotic therapy in other non-GI MALT lymphomas: study and patient characteristics
| References . | No. of patients . | Localization . | Stage . | Pathogen . | Previous therapies . | Therapy . | Detailed outcome . | FUP (mo) . |
|---|---|---|---|---|---|---|---|---|
| 31 | 1 (F/80) | Skin | I | B burgdorferi | None | Ceftriaxone IV 2 g/d × 14 d | Minimal residuals | ND |
| 32 | 1 (ND) | Skin | ND | B burgdorferi | None | “Specific antibiotic therapy for B burgdorferi” | No response | ND |
| 33 | 1 (M/72) | Skin | I | B burgdorferi | None | Ceftriaxone IV 2 g/d × 14 d | PR | 22 |
| 34 | 2 (M/28, M/38) | Skin | I | B burgdorferi | None | First line: ceftriaxone IV 2 g/d × 14 d, doxycycline 200 g/d × 21 d | First line: no response | 14/7 |
| 35 | 1 (F/88) | Skin | I | B afzelii | None | Second line: cefotaxime pulse therapy (IV 4 g TID × 2d, every 8 d, × 8 cycles), ceftriaxone IV 2 g/d × 21 d | Second line: CR 1, no response 1 PR | 25 |
| 40 | 2 (F/70, F/57) | Lung | ND | ND/HP pos | Yes/none* | Clarithromycin 200 mg/d as long-term treatment (in 1 patient only after HP-eradication therapy) | CR 1, PR 1 | ND |
| 43 | 1 (F/60) | Parotid gland | I | HP pos | None | Omeprazole, amoxicilline, and clarithromycin × 7 d | CR | 48 |
| 44 | 1 (M/69) | Thyroid gland | II | HP pos | None | Amoxicillin 1500 mg/d, clarithromycin 400 mg and lansoprazole 60 mg; daily × 14 d | CR | 5 |
| 45 | 1 (F/62) | Salivary gland | II | HP pos | None | Doxycycline 100 mg, metronidazole 500 mg, omeprazole 20 mg, and bismuth 100 mg; all TID × 14 d | CR | 22 |
| 46 | 1 (F/69) | Bladder | ND | HP pos | None | Antibiotic treatment of urinary tract infection, HP eradication | CR | 25 |
| 47 | 1 (M/59) | Bladder | I | HP pos | None | HP eradication | CR | 36 |
| 48 | 1 (F/78) | Bladder | ND | Escherichia coli | None | Trimetoprim, nitrofurantoin, and cephradine (long term) | CR | 19 |
| 18 | 1 | Breast | IV | ND | Fifth/sixth line† | Fifth line: doxycycline, sixth line: clarithromycin 500 mg BID × 6 mo | PD | ND |
| References . | No. of patients . | Localization . | Stage . | Pathogen . | Previous therapies . | Therapy . | Detailed outcome . | FUP (mo) . |
|---|---|---|---|---|---|---|---|---|
| 31 | 1 (F/80) | Skin | I | B burgdorferi | None | Ceftriaxone IV 2 g/d × 14 d | Minimal residuals | ND |
| 32 | 1 (ND) | Skin | ND | B burgdorferi | None | “Specific antibiotic therapy for B burgdorferi” | No response | ND |
| 33 | 1 (M/72) | Skin | I | B burgdorferi | None | Ceftriaxone IV 2 g/d × 14 d | PR | 22 |
| 34 | 2 (M/28, M/38) | Skin | I | B burgdorferi | None | First line: ceftriaxone IV 2 g/d × 14 d, doxycycline 200 g/d × 21 d | First line: no response | 14/7 |
| 35 | 1 (F/88) | Skin | I | B afzelii | None | Second line: cefotaxime pulse therapy (IV 4 g TID × 2d, every 8 d, × 8 cycles), ceftriaxone IV 2 g/d × 21 d | Second line: CR 1, no response 1 PR | 25 |
| 40 | 2 (F/70, F/57) | Lung | ND | ND/HP pos | Yes/none* | Clarithromycin 200 mg/d as long-term treatment (in 1 patient only after HP-eradication therapy) | CR 1, PR 1 | ND |
| 43 | 1 (F/60) | Parotid gland | I | HP pos | None | Omeprazole, amoxicilline, and clarithromycin × 7 d | CR | 48 |
| 44 | 1 (M/69) | Thyroid gland | II | HP pos | None | Amoxicillin 1500 mg/d, clarithromycin 400 mg and lansoprazole 60 mg; daily × 14 d | CR | 5 |
| 45 | 1 (F/62) | Salivary gland | II | HP pos | None | Doxycycline 100 mg, metronidazole 500 mg, omeprazole 20 mg, and bismuth 100 mg; all TID × 14 d | CR | 22 |
| 46 | 1 (F/69) | Bladder | ND | HP pos | None | Antibiotic treatment of urinary tract infection, HP eradication | CR | 25 |
| 47 | 1 (M/59) | Bladder | I | HP pos | None | HP eradication | CR | 36 |
| 48 | 1 (F/78) | Bladder | ND | Escherichia coli | None | Trimetoprim, nitrofurantoin, and cephradine (long term) | CR | 19 |
| 18 | 1 | Breast | IV | ND | Fifth/sixth line† | Fifth line: doxycycline, sixth line: clarithromycin 500 mg BID × 6 mo | PD | ND |